Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib versus everolimus in previously treated advanced neuroendocrine tumors
2025-521043-20-00Phase 3Authorised
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in apudoma (NET) comparing Zanzalintinib with Everolimus (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2026; status: authorised.
02
Drugs
zanzalintinibeverolimus
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2025-521043-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521043-20-00.